Skip to main content
Novartis Oncology Universal Co-pay Program

You may be eligible for immediate co-pay savings on your next prescription of TAFINLAR or MEKINIST.


  • Eligible patients with private insurance may pay $0 per month ($0 per month for a 30-day supply of TAFINLAR and $0 for a 30-day supply of MEKINIST). Co-pay of $0 is only for TAFINLAR and MEKINIST combination therapy

  • Novartis will pay the remaining co-pay, up to $15,000 per calendar year, per product*  

Novartis Universal Co-pay Card

*Limitations apply. This offer is only available to patients with private insurance. The program is not available for patients who are enrolled in Medicare, Medicaid, or any other federal or state health care program. Novartis reserves the right to rescind, revoke, or amend this program without notice. For full Terms and Conditions, visit or call 1-877-577-7756.

To find out if you are eligible for the Universal Co-Pay Program, call 1-877-577-7756 or visit

See If You're Eligible

Patient Assistance Now Oncology
Patient Assistance Now Oncology (PANO)

Our Patient Assistance Now Oncology (PANO) program was created to assist you with accessing your Novartis medicine(s)—from insurance verification to financial assistance—all through a knowledgeable and supportive call center.

Program overview

Novartis Oncology is committed to helping you get the Novartis medicine(s) you need. Access to medicine(s) can sometimes be difficult or confusing. PANO offers resources and support designed specifically to help make that process easier.* PANO can offer the following services:

  • Help with understanding your insurance coverage and financial responsibilities throughout the insurance verification process

  • Aid with identifying the pharmacies covered by your insurance plan

  • Insurance and Medicare education

  • Information about financial assistance that may be available*

  • Patient Support Counselors who are able to provide information in more than 160 languages

  • One single point of contact to help guide you through getting access to the Novartis medicine(s) prescribed by your doctor

*Novartis Pharmaceuticals Corporation does not guarantee success in obtaining reimbursement or financial assistance. Third-party payment for medical products and services is affected by numerous factors, not all of which can be anticipated or resolved.

To learn more, call 1-800-282-7630 or visit

Free 30-Day Trial

If you have been prescribed TAFINLAR + MEKINIST, you may be eligible to receive a free 30-day supply shipped directly to your home or another convenient location, which will allow you to start your treatment quickly.

No purchase of TAFINLAR + MEKINIST or any other product is required.

You may also be eligible to participate in the PANO Access Program, which provides a free dose of medication with the possibility of obtaining 1 or more free refills. Program rules may vary.

Ask your health care professional to help you apply for the PANO Free Trial and Access Program.

Important Safety Information

TAFINLAR and MEKINIST may cause serious side effects, including:

Risk of new cancers. TAFINLAR, when used in combination with MEKINIST, may cause a type of skin cancer called cutaneous squamous cell carcinoma, keratoacanthoma, basal cell carcinoma, or melanoma. Talk with your health care provider about your risk for these cancers. Check your skin and tell your health care provider right away about any skin changes, including a new wart, skin sore, or reddish bump that bleeds or does not heal, or a change in size or color of a mole.

Your health care provider should check your skin before you start treatment, and every 2 months while on treatment, to look for any new skin cancers. Your health care provider should continue to check your skin for 6 months after you stop taking TAFINLAR and MEKINIST.

Approved Uses

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to treat people with a type of skin cancer called melanoma:

  • that has spread to other parts of the body (metastatic) or cannot be removed by surgery (unresectable), and

  • that has a certain type of abnormal “BRAF” (V600E or V600K mutation-positive) gene

TAFINLAR and MEKINIST are prescription medicines that can be used in combination to help prevent melanoma that has a certain type of abnormal “BRAF” gene from coming back after the cancer has been removed by surgery.